GlassScriptPhysician profile
Gopika N Are
NPI 1629159702
$3,581.85
in general payments reported to CMS, 2019-2025
28 companies · $744 in 2025
The $744 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $122 · 2021: $302 · 2022: $705 · 2023: $913 · 2024: $489 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $368.20 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $359.71 | 2021-2025 | |
| Abbvie INC. | $341.05 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $308.95 | 2023-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $293.14 | 2019-2025 | Injectafer |
| Agile Therapeutics, INC. | $265.53 | 2021-2024 | Twirla |
| Merck Sharp & Dohme LLC | $171.93 | 2019-2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $167.82 | 2022-2025 | Accrufer |
| Organon LLC | $163.78 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $113.44 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $105.54 | 2022-2023 | Phexxi |
| Hologic Sales and Service, LLC | $98.79 | 2019-2025 | Thinprep 2000 Processor |
| Pfizer INC. | $93.81 | 2022-2025 | |
| Biogen, INC. | $86.42 | 2024-2025 | Zurzuvae |
| Millicent US INC | $83.70 | 2025 | Femlyv |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $81.97 | 2021-2022 | |
| Myriad Women'S Health, INC. | $62.19 | 2023 | Myrisk |
| Coopersurgical, INC. | $61.49 | 2020-2024 | Paragard T 380a |
| Lupin INC. | $57.67 | 2019-2020 | |
| Scynexis, INC. | $56.32 | 2022 | |
| Myovant Sciences INC. | $43.19 | 2021-2022 | |
| Therapeuticsmd, INC. | $41.38 | 2021-2022 | |
| Aspira Women'S Health INC | $40.36 | 2022 | |
| Dexcom, INC. | $34.44 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $31.94 | 2025 | |
| Mycovia Pharmaceuticals, INC. | $19.03 | 2023 | Vivjoa |
| Amag Pharmaceuticals, INC. | $16.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopika Are listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.